On Mar. 31, 2020, Luminex announced it had received $642,450 in funding from the Biomedical Advanced Research and Development Authority. These funds will help support development, testing, and submission later this week for an Emergency Use Authorization for the ARIES SARS-CoV-2 Assay.

This assay runs on the company’s sample-to-answer ARIES System, an U.S. Food and Drug Administration-cleared, automated molecular diagnostics platform for moderate complexity labs.